sparfloxacin has been researched along with Cross Infection in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cluzel, M; Dabernat, H; Derlot, E; Exmelin, L; Kitzis, MD; Le Noc, P; Muller-Serieys, C; Reverdy, ME; Scheftel, JM; Soussy, CJ; Thabaut, A | 1 |
| Bale, MJ; Doebbeling, BN; Pfaller, MA; Wenzel, RP | 1 |
2 other study(ies) available for sparfloxacin and Cross Infection
| Article | Year |
|---|---|
[In vitro antibacterial activity of a new fluoroquinolone, sparfloxacin, against nosocomial bacteria, and concordance curve].
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Cross Infection; Enterobacteriaceae; Escherichia coli; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; In Vitro Techniques; Quinolones; Regression Analysis | 1996 |
Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates.
Topics: Amikacin; Anti-Infective Agents; Cephalosporins; Ciprofloxacin; Cross Infection; Enterobacteriaceae; Fluoroquinolones; Gram-Negative Bacteria; Humans; Imipenem; Pseudomonas aeruginosa; Sepsis; Tobramycin | 1990 |